As reported by New Scientist, the swiss pharma company Novartis have just had the green light to sell their cannabis-based drug, Sativex to Australia, Asia the Middle East and Africa. The pharmaceutical company already sell the drug in the UK and Spain.
Sativex combines two active components of cannabis to help treat the involuntary muscle movements experienced by those with multiple sclerosis. It is also on trial in the US to help treat cancer pain.
The drug is manufactured by GW Pharmaceuticals based in Porton Down. Justin Gover, managing director of GW Pharmaceuticals stated, “Attracting a company the calibre of Novartis does send a final message that there’s serious science supporting this area.”
Are you looking for a new position in the pharmaceutical industry? Click here to search our current pharmaceutical jobs online now.